Yoon-Jae Cho

Yoon-Jae Cho

Auto-generated profile, based on publicly available information

Yoon-Jae Cho

Papé Pediatric Research Institute, Division of Pediatric Neurology, Department of Pediatrics, Oregon Health and Sciences University, Portland, OR

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2018 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
MIM. Iv
M. Iv
MZM. Zhou
M. Zhou
KSK. Shpanskaya
K. Shpanskaya
Sébastien PerreaultSébastien Perreault
Sébastien Perreault
ZWZ. Wang
Z. Wang
KYK.W. Yeom
K.W. Yeom
BACKGROUND AND PURPOSE: Distinct molecular subgroups of pediatric medulloblastoma confer important differences in prognosis and therapy. Currently, tissue sampling is the only method to obtain information for classification. Our goal was to develop and validate radiomic and machine learning approaches for predicting molecular subgroups of pediatric medulloblastoma. MATERIALS AND METHODS: In this multi-institutional retrospective study, we evaluated MR imaging datasets of 109 pediatric patients with medulloblastoma from 3 children9s hospitals from January 2001 to January 2014. A computational framework was developed to extract MR imaging–based radiomic features from tumor segmentations, and we tested 2 predictive models: a double 10-fold cross-validation using a combined dataset consisting of all 3 patient cohorts and a 3-dataset cross-validation, in which training was performed on 2 cohorts and testing was performed on the third independent cohort. We used the Wilcoxon rank sum test for feature selection with assessment of area under the receiver operating characteristic curve to evaluate model performance. RESULTS: Of 590 MR imaging–derived radiomic features, including intensity-based histograms, tumor edge-sharpness, Gabor features, and local area integral invariant features, extracted from imaging-derived tumor segmentations, tumor edge-sharpness was most useful for predicting sonic hedgehog and group 4 tumors. Receiver operating characteristic analysis revealed superior performance of the double 10-fold cross-validation model for predicting sonic hedgehog, group 3, and group 4 tumors when using combined T1- and T2-weighted images (area under the curve = 0.79, 0.70, and 0.83, respectively). With the independent 3-dataset cross-validation strategy, select radiomic features were predictive of sonic hedgehog (area under the curve = 0.70–0.73) and group 4 (area under the curve = 0.76–0.80) medulloblastoma. CONCLUSIONS: This study provides proof-of-concept results for the application of radiomic and machine learning approaches to a multi-institutional dataset for the prediction of medulloblastoma subgroups.

31 October 2011 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MPMarkus Priller
Markus Priller
JPJulia Pöschl
Julia Pöschl
LALeticia Abrão
Leticia Abrão
Andre von BuerenAndre von Bueren
Andre von Bueren
YCYoon-Jae Cho
Yoon-Jae Cho
USUlrich Schüller
Ulrich Schüller
Purpose: The transcription factor Forkhead box M1 (FoxM1) is a key regulator of cell-cycle progression. It is involved in the development of multiple organs, and we have previously reported on its important role for the mitotic entry of cerebellar granule neuron precursors. Constitutive expression of FoxM1 is required for the growth of multiple cancer types. This study aimed to determine its role in medulloblastoma, the most frequent malignant brain tumor in childhood that can derive from cerebellar granule neuron precursors. Experimental Design: We evaluated the expression of FoxM1 together with its prognostic value in two independent series of human medulloblastoma samples using immunohistochemistry (n = 43) and gene expression arrays (n = 193). The functional impact of FoxM1 expression was characterized by knockdown experiments in four human medulloblastoma cell lines, and the thiazole antibiotic siomycin A was tested to downregulate FoxM1 and inhibit tumor cell growth. Results: FoxM1 was highly expressed in all subtypes of medulloblastoma. Importantly, expression levels of FoxM1 significantly correlated with unfavorable clinical outcome in univariate analysis (P = 0.0005), and FoxM1 was identified as an independent prognostic marker by multivariate analysis (P = 0.037). Knockdown of FoxM1 in medulloblastoma cell lines resulted in a significant decrease of cell viability which was caused by a failure in mitotic spindle formation and caspase-dependent mitotic catastrophe. Siomycin A significantly inhibited the expression of FoxM1 and the growth of medulloblastoma cells. Conclusions: FoxM1 may be used as an additional prognostic marker and may represent a potential novel target to treat patients suffering from medulloblastoma. Clin Cancer Res; 17(21); 6791–801. ©2011 AACR.

2 March 2022 in JCO Precision Oncology
Verified
Journal Article
Open access
JHJacob J. Henderson
Jacob J. Henderson
ADAnirban Das
Anirban Das
DMDaniel Morgenstern
Daniel Morgenstern
SSSumedha Sudhaman
Sumedha Sudhaman
VBVanessa Bianchi
Vanessa Bianchi
UTUri Tabori
Uri Tabori
Two targets with one arrow: #Immunotherapy as single treatment for synchronous RRD #glioblastoma and #metastatic cancers.

1 September 2014 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
PDF file
AWA. Wang
A. Wang
SPS. Partap
S. Partap
KYK. Yeom
K. Yeom
MMM. Martinez
M. Martinez
HVH. Vogel
H. Vogel
IGI.C. Gibbs
I.C. Gibbs

1 January 2021
Verified
Book Chapter
Closed access
YCYoon-Jae Cho
Yoon-Jae Cho